Literature DB >> 2497766

The effect of carbamazepine on valproic acid disposition in adult volunteers.

S K Panesar1, J M Orr, K Farrell, R W Burton, K Kassahun, F S Abbott.   

Abstract

1. Pharmacokinetic parameters for valproic acid (VPA) were determined before and following 2 weeks of carbamazepine (CBZ) administration in five healthy male volunteers. Mean VPA dosage was 16.4 mg kg-1 day-1. CBZ dosage was started at 100 mg twice daily and increased after 1 week to a total daily dose of 300 mg. 2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1). Mean VPA elimination rate constant increased from 0.051 +/- 0.011 to 0.067 +/- 0.011 h-1 (P less than 0.05) after CBZ administration. 3. Mean area under the serum concentration vs time curve decreased from 675.0 +/- 130.5 to 475.7 +/- 75.7 mg l-1 h (P less than 0.05) after CBZ administration. Mean serum VPA half-life decreased from 14.0 +/- 2.4 to 10.6 +/- 1.4 h (P less than 0.05). Mean serum VPA trough concentrations decreased from 44.0 +/- 16.7 to 27.0 +/- 10.4 micrograms ml-1 (P less than 0.05). 4. A significant change was not observed in the mean VPA volume of distribution after CBZ coadministration suggesting that enzyme induction rather than a competition for plasma protein binding sites was involved in this interaction. 5. Despite the increased clearance of VPA, the urinary recovery of VPA or conjugate did not increase after CBZ administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2497766      PMCID: PMC1379830          DOI: 10.1111/j.1365-2125.1989.tb05372.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

Review 1.  Metabolism and Pharmacolinetics of Carbamazepine.

Authors:  P L Morselli; A Frigerio
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

Review 2.  Plasma and tissue binding considerations in drug disposition.

Authors:  G R Wilkinson
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

3.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 4.  Interactions between anticonvulsants and other commonly prescribed drugs.

Authors:  H Kutt
Journal:  Epilepsia       Date:  1984       Impact factor: 5.864

5.  Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.

Authors:  W G Rapeport; G T McInnes; G G Thompson; G Forrest; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

6.  Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine.

Authors:  J Wagner; K Schmid
Journal:  Xenobiotica       Date:  1987-08       Impact factor: 1.908

7.  Effects of carbamazepine on valproic acid kinetics in normal subjects.

Authors:  T A Bowdle; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

8.  Routine monitoring of carbamazepine and carbamazepine-10,11-epoxide in plasma by high-performance liquid chromatography using 10-methoxycarbamazepine as internal standard.

Authors:  A A Elyas; N Ratnaraj; V D Goldberg; P T Lascelles
Journal:  J Chromatogr       Date:  1982-08-13

9.  Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy.

Authors:  F Hoffmann; G E von Unruh; B C Jancik
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Interaction between valproic acid and carbamazepine: an in vitro study of protein binding.

Authors:  G F Mattson; R H Mattson; J A Cramer
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

View more
  6 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.

Authors:  Todd M Conner; Vahagn C Nikolian; Patrick E Georgoff; Manjunath P Pai; Hasan B Alam; Duxin Sun; Ronald C Reed; Tao Zhang
Journal:  Eur J Pharm Sci       Date:  2017-10-10       Impact factor: 4.384

4.  Establishing individual metabolite patterns for patients on valproate therapy.

Authors:  U Kreher; J Darius; F Wien
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.569

Review 5.  Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

Authors:  B Burchell; M W Coughtrie
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

6.  A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012.

Authors:  Zahra Tolou-Ghamari; Mohammad Zare; Jafar Mehvari Habibabadi; Mohammad Reza Najafi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.